{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:09:07Z","timestamp":1759882147809,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.rgmx.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T17:49:01Z","timestamp":1558028941000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efecto sobre el pH intrag\u00e1strico de 20 mg de levopantoprazol versus 40 mg de pantoprazol rac\u00e9mico durante los primeros 7 d\u00edas de tratamiento en pacientes con enfermedad por reflujo gastroesof\u00e1gico"],"prefix":"10.1016","volume":"85","author":[{"given":"J.M.","family":"Remes-Troche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.D.","family":"Garc\u00eda Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rojas-Loureiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Rivera-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Reyes-Huerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Amieva-Balmori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rgmx.2019.02.006_bib0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/j.1875-9114.1997.tb03675.x","article-title":"Proton pump inhibitors and acid-related diseases","volume":"17","author":"Sachs","year":"1997","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0165","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14656566.2017.1361407","article-title":"A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD)","volume":"18","author":"Savarino","year":"2017","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0170","first-page":"208","article-title":"Diagnosis and treatment of gastroesophageal reflux disease: recommendations of the Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda","volume":"81","author":"Huerta-Iga","year":"2016","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.23736\/S0391-1977.17.02745-6","article-title":"Diagnosis and management of Zollinger-Ellison syndrome in 2018","volume":"43","author":"De Angelis","year":"2018","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Alimentar Pharm Ther"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4321\/S1130-01082012000700006","article-title":"Proton pump inhibitors in gastroesophageal reflux disease: \u00aba custom-tailored therapeutic regimen\u00bb","volume":"104","author":"Sobrino-Coss\u00edo","year":"2012","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm.2014.20.1.6","article-title":"New and future drug development for gastroesophageal reflux disease","volume":"20","author":"Maradey-Romero","year":"2014","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0195","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1517\/14656560903198978","volume":"10","author":"Aslam","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0200","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0205","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/MCG.0b013e318224d4ba","article-title":"Control of Intragastric pH and Its Relationship to Gastroesophageal Reflux Disease Outcomes","volume":"45","author":"Katz","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0215","first-page":"441","article-title":"Interacciones en el uso de anti\u00e1cidos, protectores de la mucosa y antisecretores g\u00e1stricos","volume":"29","author":"De las Salas-Mart\u00ednez","year":"2013","journal-title":"Salud Uninorte (Barranquilla, Col.)"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2005.02339.x","article-title":"Efficacy of esomeprazole 40mg vs. lansoprazole 30mg for healing moderate to severe erosive oesophagitis","volume":"21","author":"Fennerty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0225","first-page":"469","article-title":"Recent advances in chirally pure proton pump inhibitors","volume":"105","author":"Pai","year":"2007","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0230","first-page":"112","article-title":"Chiral switch in PPI therapy","volume":"22","author":"Pai","year":"2006","journal-title":"Select BMJ"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0235","first-page":"160","article-title":"[Characterization and stability of S (-) pantoprazole sodium hydrates]","volume":"25","author":"Bei","year":"2017","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0240","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1211\/0022357056361","article-title":"Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs","volume":"57","author":"Cao","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0245","first-page":"1","article-title":"Comparison of the effects of pantoprazole enantiomers on gastric mucosal lesions and gastric epithelial cells in rats","volume":"50","author":"Cao","year":"2004","journal-title":"Yihu Keji Qikan"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0250","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.3748\/wjg.v12.i37.6017","article-title":"Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease","volume":"12","author":"Pai","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0255","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","article-title":"Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification","volume":"45","author":"Lundell","year":"1999","journal-title":"Gut."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0260","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5056\/jnm14014","article-title":"Validation and diagnostic usefulness of gastroesophageal reflux disease questionnaire in a primary care level in M\u00e9xico","volume":"20","author":"Zavala-Gonzales","year":"2014","journal-title":"J Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00044011-200828050-00001","article-title":"Stereoselective disposition of proton pump inhibitors","volume":"28","author":"Andersson","year":"2008","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0270","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2125.2005.02566.x","article-title":"Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes","volume":"61","author":"Miura","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1520-636X(1997)9:1<17::AID-CHIR4>3.0.CO;2-D","article-title":"Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole\u2014a preliminary study","volume":"9","author":"Tanaka","year":"1997","journal-title":"Chirality."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0280","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00228-004-0809-1","article-title":"Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes","volume":"60","author":"Miura","year":"2004","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0285","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1067\/mcp.2001.113723","article-title":"Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin","volume":"69","author":"Tanaka","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0290","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s11095-005-6807-x","article-title":"Pharmacokinetic differences between pantoprazole enantiomers in rats","volume":"22","author":"Xie","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.rgmx.2019.02.006_bib0295","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0009-9236(97)90081-3","article-title":"Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4\u0301 -hydroxylation phenotype and genotype","volume":"62","author":"Tanaka","year":"1997","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0300","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000200917","article-title":"Appropriate acid suppression for the management of gastro-oesophageal reflux disease","volume":"51","author":"Bell","year":"1992","journal-title":"Digestion."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0305","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s10620-012-2297-y","article-title":"Efficacy of S-pantoprazole 20mg compared with pantoprazole 40mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial","volume":"57","author":"Cho","year":"2012","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.rgmx.2019.02.006_bib0310","first-page":"733","article-title":"Efficacy and safety of intravenous S-pantoprazole in the treatment of moderate to severe gastroesophageal reflux disease (GERD) and\/or peptic ulcers","volume":"2","author":"Jain","year":"2008","journal-title":"Pharmacologyonline"}],"container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090619300527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090619300527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:46:30Z","timestamp":1759812390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0375090619300527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0375090619300527"],"URL":"https:\/\/doi.org\/10.1016\/j.rgmx.2019.02.006","relation":{},"ISSN":["0375-0906"],"issn-type":[{"type":"print","value":"0375-0906"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efecto sobre el pH intrag\u00e1strico de 20mg de levopantoprazol versus 40mg de pantoprazol rac\u00e9mico durante los primeros 7 d\u00edas de tratamiento en pacientes con enfermedad por reflujo gastroesof\u00e1gico","name":"articletitle","label":"Article Title"},{"value":"Revista de Gastroenterolog\u00eda de M\u00e9xico","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmx.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}